Invention Grant
US09174981B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
有权
取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-甲酰胺化合物作为III型受体酪氨酸激酶抑制剂
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/docs/US/2015-11-03/US09174981B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
- Patent Title (中): 取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-甲酰胺化合物作为III型受体酪氨酸激酶抑制剂
-
Application No.: US13994048Application Date: 2011-12-13
-
Publication No.: US09174981B2Publication Date: 2015-11-03
- Inventor: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
- Applicant: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
- Applicant Address: US CO Boulder
- Assignee: Array BioPharma Inc.
- Current Assignee: Array BioPharma Inc.
- Current Assignee Address: US CO Boulder
- Agency: Viksnins Harris & Padys PLLP
- Agent Sarah S. Mastous
- International Application: PCT/US2011/064549 WO 20111213
- International Announcement: WO2012/082689 WO 20120621
- Main IPC: C07D471/04
- IPC: C07D471/04
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/abs-image/US/2015/11/03/US09174981B2/abs.jpg.150x150.jpg)
Abstract:
Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Public/Granted literature
Information query
